With regard to the potential CD47 targeting MOAs of HX009, the anti-lymphoma effect could be attributed to targeting to CD47 either on tumor cells or on Teff CD47 (or even other immune cells in TME), or on both. This evidence concerns the gene CD47 and lymphoma.